This article appeared in Fierce Biotech, March 2 2022
Epsilogen Ltd was profiled in BioWorld on March 2, 2022.
This article first appeared in Drug Discovery World, Spring 2021, Volume 22, Issue 2.
Epsilogen: co-opting IgE antibodies against cancer
Epsilogen Ltd was profiled in BioCentury’s Emerging Company Profile on June 5, 2020.
Emerging Company Profile: IGEM Therapeutics has been spun out of King’s College London to evaluate the use of IgE-based monoclonal antibodies for the treatment of cancer, including difficult-to-reach solid tumors….
See the article in full here: https://scrip.pharmaintelligence.informa.com/SC123214/IGEM-Therapeutics-Pursuing-Novel-IgE-Antibodies-For-Solid-Tumors
Not to be Sneezed At
One of the stand-out technologies discussed by London-based immuno-oncology start-up Epsilogen was in antibody therapeutics…..
See the article in full here: https://www.genengnews.com/gen-exclusives/biotrinity-conference-focuses-on-nextgen-healthcare/77901102